The global market for Erythropoietin Drugs was estimated at US$11.6 Billion in 2023 and is projected to reach US$15.5 Billion by 2030, growing at a CAGR of 3.7% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. ![Erythropoietin Drugs Market]( "Erythropoietin Drugs Market")
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Epoetin-Alfa Drugs segment, which is expected to reach US$8.3 Billion by 2030 with a CAGR of 3.9%. The Darbepoetin-Alfa Drugs segment is also set to grow at 4.2% CAGR for the next 8-year period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $3.5 Billion in 2023, and China, forecasted to grow at an impressive 3.4% CAGR to reach $2.7 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Erythropoietin Drugs Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Erythropoietin Drugs Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Erythropoietin Drugs Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players such as Jiangsu Wanbang Biochemical Pharmaceuticals Co. Ltd, Kyowa Kirin Co., Ltd., Netmeds Marketplace Ltd., and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Select Competitors (Total 12 Featured):
- Jiangsu Wanbang Biochemical Pharmaceuticals Co. Ltd
- Kyowa Kirin Co., Ltd.
- Netmeds Marketplace Ltd.
- Stafford Pharmacy & Home Healthcare
- XTL Biopharmaceuticals Ltd.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of COVID-19 and a Looming Global Recession
- Erythropoietin Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Erythropoietin Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- Table 2: World Recent Past, Current & Future Analysis for Erythropoietin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 3: World Historic Review for Erythropoietin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 4: World 16-Year Perspective for Erythropoietin Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
- Table 5: World Recent Past, Current & Future Analysis for Kidney Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 6: World Historic Review for Kidney Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 7: World 16-Year Perspective for Kidney Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- Table 8: World Recent Past, Current & Future Analysis for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 9: World Historic Review for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 10: World 16-Year Perspective for Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- Table 11: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 12: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 13: World 16-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- Table 14: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 15: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 16: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- Table 17: World Recent Past, Current & Future Analysis for Epoetin-alfa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 18: World Historic Review for Epoetin-alfa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 19: World 16-Year Perspective for Epoetin-alfa by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- Table 20: World Recent Past, Current & Future Analysis for Darbepoetin-alfa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 21: World Historic Review for Darbepoetin-alfa by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 22: World 16-Year Perspective for Darbepoetin-alfa by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- Table 23: World Recent Past, Current & Future Analysis for Epoetin-beta by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 24: World Historic Review for Epoetin-beta by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 25: World 16-Year Perspective for Epoetin-beta by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- Table 26: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 27: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 28: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
UNITED STATES
- Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- Table 29: USA Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 30: USA Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 31: USA 16-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2014, 2024 & 2030
- Table 32: USA Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 33: USA Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 34: USA 16-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2014, 2024 & 2030
CANADA
- Table 35: Canada Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 36: Canada Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 37: Canada 16-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2014, 2024 & 2030
- Table 38: Canada Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 39: Canada Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 40: Canada 16-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2014, 2024 & 2030
JAPAN
- Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- Table 41: Japan Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 42: Japan Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 43: Japan 16-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2014, 2024 & 2030
- Table 44: Japan Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 45: Japan Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 46: Japan 16-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2014, 2024 & 2030
CHINA
- Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- Table 47: China Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 48: China Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 49: China 16-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2014, 2024 & 2030
- Table 50: China Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 51: China Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 52: China 16-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2014, 2024 & 2030
EUROPE
- Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- Table 53: Europe Recent Past, Current & Future Analysis for Erythropoietin Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- Table 54: Europe Historic Review for Erythropoietin Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 55: Europe 16-Year Perspective for Erythropoietin Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
- Table 56: Europe Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 57: Europe Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 58: Europe 16-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2014, 2024 & 2030
- Table 59: Europe Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 60: Europe Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 61: Europe 16-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2014, 2024 & 2030
FRANCE
- Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- Table 62: France Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 63: France Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 64: France 16-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2014, 2024 & 2030
- Table 65: France Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 66: France Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 67: France 16-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2014, 2024 & 2030
GERMANY
- Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- Table 68: Germany Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 69: Germany Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 70: Germany 16-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2014, 2024 & 2030
- Table 71: Germany Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 72: Germany Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 73: Germany 16-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2014, 2024 & 2030
ITALY
- Table 74: Italy Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 75: Italy Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 76: Italy 16-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2014, 2024 & 2030
- Table 77: Italy Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 78: Italy Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 79: Italy 16-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2014, 2024 & 2030
UNITED KINGDOM
- Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- Table 80: UK Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 81: UK Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 82: UK 16-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2014, 2024 & 2030
- Table 83: UK Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 84: UK Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 85: UK 16-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2014, 2024 & 2030
REST OF EUROPE
- Table 86: Rest of Europe Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 87: Rest of Europe Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 88: Rest of Europe 16-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2014, 2024 & 2030
- Table 89: Rest of Europe Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 90: Rest of Europe Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 91: Rest of Europe 16-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2014, 2024 & 2030
ASIA-PACIFIC
- Erythropoietin Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- Table 92: Asia-Pacific Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 93: Asia-Pacific Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 94: Asia-Pacific 16-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2014, 2024 & 2030
- Table 95: Asia-Pacific Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 96: Asia-Pacific Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 97: Asia-Pacific 16-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2014, 2024 & 2030
REST OF WORLD
- Table 98: Rest of World Recent Past, Current & Future Analysis for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 99: Rest of World Historic Review for Erythropoietin Drugs by Application - Kidney Disorders, Hematology, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 100: Rest of World 16-Year Perspective for Erythropoietin Drugs by Application - Percentage Breakdown of Value Sales for Kidney Disorders, Hematology, Cancer and Other Applications for the Years 2014, 2024 & 2030
- Table 101: Rest of World Recent Past, Current & Future Analysis for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- Table 102: Rest of World Historic Review for Erythropoietin Drugs by Drug Type - Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- Table 103: Rest of World 16-Year Perspective for Erythropoietin Drugs by Drug Type - Percentage Breakdown of Value Sales for Epoetin-alfa, Darbepoetin-alfa, Epoetin-beta and Other Drug Types for the Years 2014, 2024 & 2030
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Jiangsu Wanbang Biochemical Pharmaceuticals Co. Ltd
- Kyowa Kirin Co., Ltd.
- Netmeds Marketplace Ltd.
- Stafford Pharmacy & Home Healthcare
- XTL Biopharmaceuticals Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 179 |
| Published | April 2025 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 11.6 Billion |
| Forecasted Market Value ( USD | $ 15.5 Billion |
| Compound Annual Growth Rate | 3.7% |
| Regions Covered | Global |
